News

What Latest EU 2024/1860 Amendment Means for IVD Manufacturers

Key deadlines and questions in vitro diagnostic manufacturers need to consider to comply with IVDR Amendment EU 2024/1860.

Published on:
November 12, 2024

This article was originally published in Today's Clinical Lab.

The regulatory landscape for in vitro diagnostic (IVD) manufacturers in the European Union is evolving, bringing about significant changes. The latest amendment to the In Vitro Diagnostic Regulation (IVDR), EU 2024/1860, took effect on July 9, 2024, introducing a series of important updates. These include the phased introduction of the EUDAMED medical device database, new supply chain obligations, and revised transitional provisions for IVDs.

The IVDR, which replaced the former In Vitro Diagnostic Directive (IVDD), set forth stringent requirements for the development, manufacturing, and distribution of IVDs within the EU. Initially, all IVD manufacturers were expected to comply with these new regulations by May 26, 2022. However, the reality of this transition has proven challenging for many companies, leading to the introduction of several amendments designed to provide more time for compliance. The latest amendment, EU 2024/1860, extends the transition period for legacy devices by an additional three to five years, depending on the device's risk class.

Manufacturers might view this as just another extension, possibly leading them to slow down or pause their transition efforts, believing there will be less scrutiny from competent authorities or notified bodies (NBs). However, understanding the limitations, deadlines, and specific requirements of this amendment is essential for manufacturers who wish to continue operating within the EU market without facing severe regulatory and business risks.

Key questions IVD manufacturers need to consider for EU 2024/1860

To fully grasp the implications of the IVDR Amendment EU 2024/1860 and to prepare adequately, manufacturers should ask themselves the following questions:

  • Do I fully understand the limitations for legacy devices under the amended transition timelines?
  • Am I aware of what constitutes significant changes in design and intended purpose that could invalidate these amended timelines?
  • Do I know what I need to prepare to have a quality management system (QMS) that meets IVDR Article 10(8) requirements by May 2025, including economic operator controls, risk management, performance evaluation, post-market surveillance (PMS), and vigilance?
  • Do I know what I need to prepare for lodging the formal application with the NB and then signing an agreement with the NB starting in May 2025? (The deadline depends on the risk class of the IVD device; see Table 1 below).
  • Do I understand the required supply chain controls for my economic operators, critical subcontractors, and crucial supplies?
  • Is my resource planning adequate to ensure a timely transition to IVDR compliance?
  • Do I understand the consequences, costs, and business risks of failing to comply with these requirements?


Class under IVDR QMS IVDR ready (Article 10(8)) Application to be lodged with NB Agreement to be signed with NB Final IVDR deadline for legacy devices
Class D May 26, 2025 May 26, 2025 September 26, 2025 December 31, 2027
Class C May 26, 2025 May 26, 2026 September 26, 2026 December 31, 2028
Class B and Class A sterile May 26, 2025 May 26, 2027 September 26, 2027 December 31, 2029

Table 1: IVD manufacturers need to be aware of various upcoming deadlines to comply with EU 2024/1860.

If the answer to any of these seven questions is not a clear “yes,” this could have a significant impact on your business in the EU.  

For instance, if by May 2025 your QMS fails to include the necessary procedures outlined in Article 10(8), the amended timelines may no longer apply to your device. Similarly, if the intended purpose of your product is not fully defined according to Annex I, Section 20.4.1(c), NBs will not accept your application. This is true for software and systems. If your product does not meet and maintain compliance with state-of-the-art standards, it may no longer be considered compliant with the IVDD.

You may ask yourself, "Who will be responsible for ensuring my QMS complies with Article 10(8) by May 2025?" The competent authority has the power to perform unannounced inspections, and it will certainly review your compliance when you submit your application to the NB for CE marking. Even if your submission is after May 2025, the digital documentation systems used by most manufacturers make it easy for auditors to trace back and verify what was implemented by that deadline.

Meeting these amended deadlines also means accounting for potentially lengthy NB review timelines. The amendment indicates an average NB review time of 18 months. However, this can vary significantly based on the quality of your documentation. This is why it’s essential to plan your internal activities and timelines to ensure your IVD complies with IVDR requirements.

This effort may involve significant documentation efforts, including the creation of general safety and performance requirements, performance evaluation plans and reports, PMS plans and reports, and post-market performance follow-up plans, and reports. In fact, it may even require new analytical testing or even clinical performance testing to demonstrate the clinical evidence.

NBs have already warned that delaying applications will result in submissions being placed at the end of the review queue, increasing the risk of delayed assessment. They have also indicated that if applications for legacy devices are submitted too close to the cut-off deadline, they may not be able to process them in time. Consider the perspective of the NBs: They need to manage their resources effectively, which requires predictable numbers of IVD submissions to plan accordingly.

As a consequence, the deadlines for submitting applications and signing agreements with the NBs are crucial for manufacturers of legacy devices aiming to take advantage of the extended transition periods. In fact, from a business standpoint, these deadlines should be treated as internal milestones.

A strategic approach to navigating new regulations

In navigating the complexities of the IVDR, particularly with the recent EU 2024/1860 amendment, it’s safe to say that strategic preparation is key for IVD manufacturers. In my 25 years of work experience in the IVD field, I have frequently discussed with manufacturers what constitutes an adequate level of regulatory information and how to strike a balance between meeting regulatory requirements and managing business needs.

My consistent advice as a consultant is to first conduct a brief analysis of the company's current situation and the level of documentation it has implemented. Many IVD manufacturers have not yet been audited by NBs, and due to the sheer volume of new regulatory interpretations, there is often a significant gap between what manufacturers believe they have in place and what is required to demonstrate IVDR compliance.

The old 1-10-100 rule, commonly used in design to demonstrate the costs of poor design or inadequate controls, applies here as well. Failure to comply with regulatory requirements can result in costs that are 10 to 100 times higher than anticipated. The additional costs associated with extended NB review times and higher hourly fees—recently reported to be between €300 and ~€400 per hour—underscore the importance of thorough preparation.

To mitigate these risks, manufacturers should view the deadlines for lodging applications and signing agreements with NBs as critical internal milestones. After all, these are not just administrative requirements but key aspects of maintaining the market position in the EU.

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

An extensive round-up of medical device regulatory news from November 2024 includes new and updated guidance documents, Q&As, and directives from Europe and the US, including the new EU Product Liability Directive for AI and Smart Products.

Pure Global is proud to announce its inclusion in the China Business Service Providers (BSP) directory on the International Trade Administration website.

Regulatory Update
November 20, 2024

This week in medical device regulatory news, Thailand has introduced new refer and transfer guidelines, Europe released an updated Q&A on IVDR and MDR vigilance terms, and Romania has new rules for Economic Operators.

Regulatory Update
November 13, 2024

This week, we bring you medical device regulatory update coverage from around the world, including new registration Q&A resources in Taiwan and Japan, UK relaunches ILAP pathway, Mexico will apply a new acquisition model, and more.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

Risk increases compliance chalenges under IVDR
Blog Article
What are the challenges under IVDR?

IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.

Blog Article
EU Parliament Revises MDR and IVDR

On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.

Blog Article
Language Challenges in MedTech Going Global and Our Solution

Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.

Medical device supply chain
Blog Article
Managing your medical device supply chain

The connection between supplier controls and business risks is becoming increasingly evident. In this article, we discuss perspectives on how to maintain a compliant medical device supply chain.